Epidermal Growth Factor Receptor news

All news on Epidermal Growth Factor Receptor (also known as EGFR and HER1): plants, production capacities, investments and involved companies.

16 February 2026

Lilly's Retevmo Shows Event-Free Survival Benefit in Early-Stage RET Fusion-Positive Lung Cancer

Selpercatinib significantly reduces disease recurrence risk in early-stage RET fusion-positive NSCLC. Safety profile aligns with previous trials. Detailed results pending.
10 January 2026

Johnson & Johnson's RYBREVANT® Shows Durable Responses in Challenging Colorectal Cancer

Amivantamab with chemotherapy shows promising results in metastatic colorectal cancer, maintaining responses beyond two years and addressing resistance to current therapies.
24 October 2025

Merus Reports Positive Interim Data on Petosemtamab in Metastatic Colorectal Cancer

Petosemtamab shows promising response rates in 1L and 2L mCRC, with potential as a new standard of care.
21 October 2025

Takeda Partners with Innovent on Oncology Medicines

Takeda gains rights to two late-stage cancer drugs and an option for an early-stage program, focusing on global development and commercialization outside Greater China.
13 October 2025

Merus to Present Petosemtamab Data at AACR-NCI-EORTC Conference

Petosemtamab data in metastatic colorectal cancer to be presented in plenary and poster sessions at an upcoming conference.

Who will be producing Epidermal Growth Factor Receptor in the future?

Find out with chemXplore Alpha

Learn more